Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 32
2003 58
2004 31
2005 34
2006 52
2007 44
2008 41
2009 50
2010 61
2011 47
2012 29
2013 57
2014 54
2015 61
2016 49
2017 46
2018 42
2019 34
2020 21
2021 19
2022 16
2023 19
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

773 results

Results by year

Filters applied: . Clear all
Page 1
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.
Zhao Y, Laird AD, Roberts KG, Yafawi RL, Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien SM, Jabbour EJ, Cassaday RD, Loyd MR, Olsen SR, Neale GA, Liu X, Vandendries E, Advani AS, Mullighan CG. Zhao Y, et al. Among authors: o brien sm. Blood Adv. 2024 Mar 26:bloodadvances.2023012430. doi: 10.1182/bloodadvances.2023012430. Online ahead of print. Blood Adv. 2024. PMID: 38607410
Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial.
Tam CS, Lamanna N, O'Brien SM, Qiu L, Yang K, Barnes G, Wu K, Salmi T, Brown JR. Tam CS, et al. Among authors: o brien sm. Curr Med Res Opin. 2023 Sep 27:1-7. doi: 10.1080/03007995.2023.2262378. Online ahead of print. Curr Med Res Opin. 2023. PMID: 37752892
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.
Seymour JF, Byrd JC, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O'Brien S, Brown JR, Munir T, Mato A, Stilgenbauer S, Bajwa N, Miranda P, Higgins K, John E, de Borja M, Jurczak W, Woyach JA. Seymour JF, et al. Among authors: o brien s. Blood. 2023 Aug 24;142(8):687-699. doi: 10.1182/blood.2022018818. Blood. 2023. PMID: 37390310 Free PMC article. Clinical Trial.
773 results